News|Articles|June 9, 2023

We Need the Updated Bivalent COVID-19 Booster, Don’t We?

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

At its last meeting in April of this year the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) discussed safety data as well as plans to simplify COVID-19 immunization recommendations. Before the FDA withdrawal of emergency authorization for use of monovalent mRNA vaccines, there were 11 different products being produced. That number has been reduced to 5.

It is now recommended that anyone previously vaccinated with a monovalent vaccine get a single booster dose of a bivalent formulation. Bivalent vaccines have been available for persons over the age of 12 since September 2, 2022. So, how have Americans responded to the new recommendation that all get boosted with a bivalent vaccine?

Adults over the age of 65 years are at higher risk of hospitalization and death from SARS-CoV-2 infection and, as has historically been the case with influenza vaccines, uptake is highest in this age group.

Question 1. What percent of adults over age 65 had been boosted with a COVID-19 bivalent vaccine as of April 13, 2023?

(Point of reference: 94% of this age group got the primary series with the monovalent version.)

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Latest CME

In-Person Event

Interventional Glaucoma: The Convergence of Surgical Innovation and Therapeutic Hope

October 24, 2025

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

We Need the Updated Bivalent COVID-19 Booster, Don’t We?

Question 1. What percent of adults over age 65 had been boosted with a COVID-19 bivalent vaccine as of April 13, 2023?

Newsletter

Related Content

The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care

Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...

Diagnosing DVT: Clinical Pearls for Challenging Presentations

Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD

New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive

Latest CME

Interventional Glaucoma: The Convergence of Surgical Innovation and Therapeutic Hope

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Southern Florida Psychiatry Conference

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Breast Cancer Symposia in San Antonio

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Real Psychiatry 2026

23rd Annual Winter Lung Cancer Conference®

EnVision Summit

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

43rd Annual Miami Breast Cancer Conference®

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

2nd Annual Hawaii Cancer Conference

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Expert Perspectives on Technological Advances in Cataract Surgery

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Cases and Conversations: Evidence-Based Approaches to Management of CKD in Your Patients With T2DM

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis